At the news
? NEUTRALIMPACT 5/10 SC 13D filed Nov 12, 2026 at 17:00 ET
Fairmount Funds Management LLC filed a Schedule 13D disclosing beneficial ownership of 19.99% of Mentari Therapeutics (formerly InMed Pharmaceuticals) common stock, acquired through a reverse merger and PIPE financing. The stake was obtained as part of the merger consideration and a $490M pre-closing financing, with Fairmount holding 10,555,507 shares and additional convertible preferred stock and pre-funded warrants subject to ownership limitations.
- Fairmount Funds Management LLC and affiliated entities own 19.99% of Mentari Therapeutics common stock as of November 6, 2026
- The stake consists of 10,555,507 shares of common stock directly held by Fairmount Healthcare Fund II L.P.
- Fairmount also holds 4,013 shares of Series A Non-Voting Convertible Preferred Stock convertible into 4,013,000 common shares and 1,468,222 pre-funded warrants, both subject to 19.99% beneficial ownership limitations
- The aggregate purchase price for the common stock and pre-funded warrants was $119,999,263, plus $200,000 for the Series A Preferred Stock
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access